San Diego, CA, United States of America

Christopher Efigenio

This inventor holds 1 USPTO granted patent. Top assignee: Dexcom, Inc.. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christopher Efigenio: Innovator in Biometric Security

Introduction

Christopher Efigenio is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of biometric security through his innovative patent. His work focuses on enhancing security measures by utilizing continuous biometric information monitoring.

Latest Patents

Christopher holds a patent for "Using continuous biometric information monitoring for security." This invention involves obtaining measurements of biometric information over time, such as blood glucose levels, through a wearable device. The biometric data collected can be utilized by various systems, including user computing devices and biometric monitoring platforms. These measurements play a crucial role in multi-factor authentication, generating security keys, and protecting sensitive biometric information.

Career Highlights

Christopher is currently employed at Dexcom, Inc., a company known for its advancements in diabetes management technology. His role at Dexcom allows him to apply his expertise in biometric monitoring to develop innovative solutions that enhance user security and health management.

Collaborations

Some of Christopher's notable coworkers include Matthew Lawrence Johnson and Issa Sami Salameh. Their collaboration contributes to the innovative environment at Dexcom, fostering advancements in biometric technology.

Conclusion

Christopher Efigenio's work in biometric security exemplifies the intersection of technology and health. His patent reflects a commitment to improving security measures through innovative biometric monitoring solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…